Immune checkpoint inhibitors in the treatment of cervical cancer: literature review



The incidence and mortality from cervical cancer (CC) remains high. There are few effective options among chemotherapeutic agents for the treatment of recurrent and metastatic CC. One of the novel therapeutic approaches is to induce anti-cancer immunity by immune checkpoint inhibitors (ICI). The search for prognostic biomarkers to improve the efficacy of immunotherapy is ongoing. The efficacy and safety of ICI, either used as monotherapy or in combination with chemotherapy, radiation therapy, is being evaluated in several clinical studies. Early results are promising, making ICI an important field of research in the development of novel therapies for CC.